Inflammatory cascades disrupt Treg function through epigenetic mechanisms
炎症级联反应通过表观遗传机制破坏 Treg 功能
基本信息
- 批准号:10348765
- 负责人:
- 金额:$ 49.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-10 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAdoptive Cell TransfersAdoptive TransferAnti-Inflammatory AgentsArchitectureAutomobile DrivingBindingBioinformaticsBiologyCCCTC-binding factorCD4 Positive T LymphocytesCell TherapyCell physiologyCellsChromatinChromatin LoopChromatin StructureChronicClinicComplexCrohn&aposs diseaseDNADefinityDerivation procedureDermatologicDevelopmentDiseaseDrug TargetingETS Family ProteinEnhancersEnvironmentEpigenetic ProcessEvaluationEventExposure toFOXP3 geneGenesGenetic TranscriptionGoalsGrantHumanHuman BiologyHuman EngineeringImmuneInflammationInflammatoryInflammatory Bowel DiseasesIntestinesInvestigational TherapiesKineticsLesionLymphocyteMaintenanceMalignant NeoplasmsMediatingMusNeurologicPathogenicityPathway interactionsPatientsPeripheralPhenocopyPhenotypePolycombProteinsPublic HealthPublishingRegulatory T-LymphocyteRepressor ProteinsResearchRiskRoleShapesSignal TransductionSpleenSpontaneous colitisT-LymphocyteTestingTherapeuticTherapy trialUrsidae FamilyWorkcellular engineeringcytokineepigenetic drugepigenetic therapyepigenomeepigenomicsexperiencegene networkgene repressiongut inflammationin vivoinflammatory milieuinsightlaboratory developmentnovelprogramspromotertherapeutic evaluationtherapeutic target
项目摘要
PROJECT SUMMARY/ABSTRACT
CD4+FOXP3+lymphocytes are expanded within the intestinal inflammatory lesion of Crohn’s disease (CD);
however, ongoing inflammation belies presumed anti-inflammatory function of this cell. FOXP3 is required for
differentiation and function of T regulatory (TREG) cells. FOXP3-mediated gene repression is lost in intestinal
T cells of CD patients. Indeed, “FOXP3+ Crohn’s cell (FOXP3+CD)” bears a transcriptional signal more
closely related to the pro-inflammatory TH17 cell. Derivation, function, and therapeutic implications of the
FOXP3+CD cell remain poorly understood. Our long-term goal is to dissect epigenetic mechanisms regulating
TREG cellular differentiation and function in the setting of GI inflammation. Consequently, the objective is to
identify mechanisms responsible for activation of the TH17 phenotypic transcriptional network within intestinal
FOXP3+CD cells and test therapeutic opportunities to restore their regulatory function in vivo. Our central
hypothesis is that a shared chromatin configuration between TREG and TH17 cells allows for rapid activation
of a TH17-like pro-inflammatory gene program in intestinal FOXP3+TREG cells. A set of TH17-relevant genes
are accessible, yet not active in human TREG cells. A defining feature of the TH17 program was significant
enrichment of CCCTC binding factor (CTCF) motifs. CTCF, a well-known topologically-associated domain
(TAD) insulator protein, also mediates intra-TAD chromosomal looping and enhancer-promoter interaction
regulating gene transcription. Bioinformatic analysis of this TH17 program indicates an inhibitory role for
Polycomb Repressor Complex 1 (PRC1). Deletion of PRC1 in murine FOXP3+ cells led to secretion of
prototypic TH17-like cytokines in FOXP3+ cells, and spontaneous colitis. The rationale is that with mechanistic
insight into the biology of intestinal TREG cell in inflammation, one can apply targeted FOXP3+ CD cell-directed
therapy including engineering of human TREG cells for adoptive cell therapy trials. To test the central
hypothesis and obtain the overall objective we will address the following three questions: Aim1: Why are CTCF
motifs associated with the TH17 program? Aim2: Why are TH17-associated genes accessible yet not active in
TREG cells? Aim3: Why do FOXP3+CD cells express prototypic TH17 cytokines? Upon conclusion, we will
understand the epigenetic pathways and 3D chromatin architecture spawning the FOXP3+CD cell and
mechanisms shaping their development and function. This contribution is significant as the FOXP3+CD cell is
expanded in the Crohn’s lesion, phenocopies TH17 cell which is implicated in Crohn’s disease (and other
inflammatory diseases), and represents an important epigenetic drug target for systemic or re-engineered
cellular therapy. There is general acknowledgement of risk of FOXP3+ TREG cells converting to pathogenic
FOXP3+TH17-like cells upon adoptive transfer in Crohn’s trials; yet, this project is the first to articulate both
signature and precise epigenetic events that regulate activation of the TH17 program in TREG cells.
项目总结/摘要
CD 4 + FOXP 3+淋巴细胞在克罗恩病(CD)的肠道炎性病变内扩增;
然而,持续的炎症掩盖了该细胞的假定抗炎功能。需要FOXP 3
调节性T细胞(Treg)的分化和功能。FOXP 3介导的基因抑制在肠道中丢失
CD患者的T细胞。事实上,“FOXP 3+克罗恩氏细胞(FOXP 3 +CD)”携带更多的转录信号。
与促炎性TH 17细胞密切相关。的来源、功能和治疗意义
FOXP 3 +CD细胞仍然知之甚少。我们的长期目标是剖析表观遗传机制,
TREG细胞分化和功能在胃肠道炎症的设置。因此,目标是
确定负责肠内TH 17表型转录网络激活的机制
FOXP 3 +CD细胞,并测试治疗机会以恢复其体内调节功能。我们的中央
一种假说是TREG和TH 17细胞之间共享的染色质构型允许快速活化
TH17-like proinflammatory gene program in intestinal FOXP3+TREG cells.一组TH 17相关基因
是可接近的,但在人Treg细胞中没有活性。TH 17项目的一个显著特点是
CCCTC结合因子(CTCF)基序的富集。CTCF,一个著名的拓扑关联域
(TAD)绝缘子蛋白也介导染色体内成环和增强子-启动子相互作用
调节基因转录。该TH 17程序的生物信息学分析表明,
多梳阻遏复合物1(PRC 1)。PRC 1在鼠FOXP 3+细胞中的缺失导致PRC 1的分泌。
FOXP 3+细胞中的原型TH 17样细胞因子和自发性结肠炎。基本原理是,
深入了解炎症中肠道Treg细胞的生物学,可以应用靶向FOXP 3 + CD细胞定向
本发明还提供了用于治疗包括工程改造人TREG细胞用于过继性细胞治疗试验的方法。为了测试中央
假设并获得总体目标,我们将解决以下三个问题:目标1:为什么CTCF
与TH 17项目相关的图案目标2:为什么TH 17相关基因在人类中可获得但不活跃?
Treg细胞?目的3:为什么FOXP 3 +CD细胞表达原型TH 17细胞因子?在结束时,我们将
了解产生FOXP 3 +CD细胞的表观遗传途径和3D染色质结构,
形成其发展和功能的机制。这种贡献是显著的,因为FOXP 3 +CD细胞是
在克罗恩病病变中扩增,表型模仿与克罗恩病有关的TH 17细胞(和其他
炎症性疾病),并代表了一个重要的表观遗传药物靶点,
细胞疗法人们普遍认识到FOXP 3 + Treg细胞转化为致病性Treg细胞的风险。
FOXP 3 + TH 17样细胞在克罗恩氏试验中过继转移;然而,这个项目是第一个阐明这两个
信号和精确的表观遗传事件,调节Treg细胞中TH 17程序的激活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William A Faubion其他文献
William A Faubion的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William A Faubion', 18)}}的其他基金
Inflammatory cascades disrupt Treg function through epigenetic mechanisms
炎症级联反应通过表观遗传机制破坏 Treg 功能
- 批准号:
10555213 - 财政年份:2021
- 资助金额:
$ 49.26万 - 项目类别:
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.
KLF10 通过介导 Treg 细胞中 TGFb 诱导 FOXP3 来调节结肠炎。
- 批准号:
8223136 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.
KLF10 通过介导 Treg 细胞中 TGFb 诱导 FOXP3 来调节结肠炎。
- 批准号:
8423785 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.
KLF10 通过介导 Treg 细胞中 TGFb 诱导 FOXP3 来调节结肠炎。
- 批准号:
8100826 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.
KLF10 通过介导 Treg 细胞中 TGFb 诱导 FOXP3 来调节结肠炎。
- 批准号:
8605155 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
Inflammatory cascades disrupt Treg function through epigenetic mechanisms
炎症级联反应通过表观遗传机制破坏 Treg 功能
- 批准号:
9104693 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
Inflammatory cascades disrupt Treg function through epigenetic mechanisms
炎症级联反应通过表观遗传机制破坏 Treg 功能
- 批准号:
9205208 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
Inflammatory cascades disrupt Treg function through epigenetic mechanisms
炎症级联反应通过表观遗传机制破坏 Treg 功能
- 批准号:
9720045 - 财政年份:2011
- 资助金额:
$ 49.26万 - 项目类别:
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.
KLF10 通过介导 Treg 细胞中 TGFb 诱导 FOXP3 来调节结肠炎。
- 批准号:
8123620 - 财政年份:2010
- 资助金额:
$ 49.26万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 49.26万 - 项目类别:
Research Grant